Latest News and Press Releases
Want to stay updated on the latest news?
-
Dividend amount: NOK 0.5 Declared currency: NOK Last day including right: 20 May 2021 Ex-date: 21 May 2021 Record date: 24 May 2021 Payment date: 3 June 2021 Date of approval: 20 May 2021 For...
-
Oslo, Norway, 28 April 2021 Vistin Pharma ASA (OSE: VISTIN), please find attached the call for the Annual General Meeting in Vistin Pharma, to be held on 20 May at 13:00 CEST. Due to the Covid-19...
-
Oslo, Norway, 23 April 2021 Please find attached the Annual Report for 2020 for Vistin Pharma ASA. There are no material changes in the financial statements compared to the preliminary full year...
-
Oslo, Norway, 23rd of April 2021 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the first quarter 2021 Vistin Pharma delivers another strong quarter...
-
Oslo, Norway, 16 April 2021 Vistin Pharma ASA will release its first quarter 2021 results on Friday 23rd of April 2021. Vistin Pharma will host a conference call for all shareholders and interested...
-
Intertrade Shipping AS har mandag 15. mars kjøpt 1.500.000 aksjer i Vistin Pharma ASA forNOK 23,60 pr. aksje. Intertrade Shipping AS eier etter kjøpet 12.575.000 aksjeri Vistin Pharma AS, tilsvarende...
-
Tycoon Industrier AS has today 15 March 2021 purchased 784 280 shares in Vistin Pharma at NOK 23.60 per share. Total holding is 784 280 shares after the transaction. Tycoon Industrier AS is closely...
-
Saga Pure ASA has on 15 March 2021 sold 2,284,280 shares in Vistin Pharma ASA,corresponding to 5.2% of the outstanding shares.After the transaction, Saga Pure ASA has no holding of shares or votes in...
-
Oslo, Norway, 19th of February 2021 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the fourth quarter and 2020 preliminary figures. Another strong...
-
Oslo, Norway, 12 February 2020 Vistin Pharma ASA will release its fourth quarter 2020 results on Friday 19th of February 2021. Vistin Pharma will host a conference call for all shareholders and...